Ikena Oncology Analyst Ratings
Ikena Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | 164.42% | Wedbush | → $11 | Initiates Coverage On | → Outperform |
| 08/10/2023 | 332.69% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 08/07/2023 | 332.69% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 05/24/2023 | 332.69% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 05/16/2023 | 212.5% | Credit Suisse | → $13 | Reiterates | Outperform → Outperform |
| 05/04/2023 | 332.69% | HC Wainwright & Co. | → $18 | Assumes | → Buy |
| 03/17/2023 | 428.85% | HC Wainwright & Co. | → $22 | Reiterates | → Buy |
| 03/15/2023 | 212.5% | Credit Suisse | $16 → $13 | Maintains | Outperform |
| 11/29/2022 | 284.62% | Credit Suisse | $18 → $16 | Maintains | Outperform |
| 11/29/2022 | 428.85% | HC Wainwright & Co. | $26 → $22 | Maintains | Buy |
| 11/08/2022 | 332.69% | Credit Suisse | $20 → $18 | Maintains | Outperform |
| 05/13/2022 | 380.77% | Credit Suisse | $24 → $20 | Maintains | Outperform |
| 04/13/2022 | 525% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 12/23/2021 | 500.96% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 08/13/2021 | 549.04% | Credit Suisse | $30 → $27 | Maintains | Outperform |
| 04/20/2021 | — | Jefferies | Initiates Coverage On | → Buy | |
| 04/20/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 04/20/2021 | 621.15% | Credit Suisse | → $30 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/22/2023 | 164.42% | 韋德布什 | →$11 | 開始承保 | →跑贏大盤 |
| 2023年08月10日 | 332.69% | HC Wainwright公司 | →$18 | 重申 | 購買→購買 |
| 08/07/2023 | 332.69% | HC Wainwright公司 | →$18 | 重申 | 購買→購買 |
| 2023年05月24日 | 332.69% | HC Wainwright公司 | →$18 | 重申 | 購買→購買 |
| 2023年05月16日 | 212.5% | 瑞士信貸 | →$13 | 重申 | 跑贏→跑贏大盤 |
| 05/04/2023 | 332.69% | HC Wainwright公司 | →$18 | 假設 | →購買 |
| 03/17/2023 | 428.85% | HC Wainwright公司 | →$22 | 重申 | →購買 |
| 03/15/2023 | 212.5% | 瑞士信貸 | $16→$13 | 維護 | 跑贏大盤 |
| 2022年11月29日 | 284.62% | 瑞士信貸 | $18→$16 | 維護 | 跑贏大盤 |
| 2022年11月29日 | 428.85% | HC Wainwright公司 | $26→$22 | 維護 | 買 |
| 11/08/2022 | 332.69% | 瑞士信貸 | $20→$18 | 維護 | 跑贏大盤 |
| 2022年05月13日 | 380.77% | 瑞士信貸 | $24→$20 | 維護 | 跑贏大盤 |
| 04/13/2022 | 525% | HC Wainwright公司 | $25→$26 | 維護 | 買 |
| 2021年12月23日 | 500.96% | HC Wainwright公司 | →$25 | 開始承保 | →購買 |
| 2021/08/13 | 549.04% | 瑞士信貸 | $30→$27 | 維護 | 跑贏大盤 |
| 04/20/2021 | - | 傑富瑞 | 開始承保 | →購買 | |
| 04/20/2021 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 | |
| 04/20/2021 | 621.15% | 瑞士信貸 | →$30 | 開始承保 | →跑贏大盤 |
What is the target price for Ikena Oncology (IKNA)?
Ikena Oncology(IKNA)的目標價格是多少？
The latest price target for Ikena Oncology (NASDAQ: IKNA) was reported by Wedbush on September 22, 2023. The analyst firm set a price target for $11.00 expecting IKNA to rise to within 12 months (a possible 164.42% upside). 11 analyst firms have reported ratings in the last year.
韋德布什於2023年9月22日報道了Ikena Oncology(納斯達克：IKNA)的最新目標價。這家分析公司將目標價定為11美元，預計宜家航空將在12個月內上漲至11美元(漲幅可能為164.42%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Ikena Oncology (IKNA)?
Ikena Oncology(IKNA)的最新分析師評級是多少？
The latest analyst rating for Ikena Oncology (NASDAQ: IKNA) was provided by Wedbush, and Ikena Oncology initiated their outperform rating.
對Ikena Oncology(納斯達克代碼：IKNA)的最新分析師評級是由韋德布什提供的，Ikena Oncology發起了他們的表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Ikena Oncology (IKNA)?
Ikena Oncology(IKNA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ikena Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ikena Oncology was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Ikena Oncology的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Ikena Oncology的上一次評級是在2023年9月22日提交的，所以你應該預計下一次評級將在2024年9月22日左右提供。
Is the Analyst Rating Ikena Oncology (IKNA) correct?
分析師對Ikena Oncology(IKNA)的評級正確嗎？
While ratings are subjective and will change, the latest Ikena Oncology (IKNA) rating was a initiated with a price target of $0.00 to $11.00. The current price Ikena Oncology (IKNA) is trading at is $4.16, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Ikena Oncology(IKNA)評級是以0.00美元至11.00美元的目標價啟動的。Ikena Oncology(IKNA)目前的交易價格為4.16美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。